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anti-tumor activity. We hypothesized that partial depletion of 
CD8 cells might have a similar effect as primary GVHD prophy- 
laxis after alIo-PBSCT. We report a series of 25 patients (pts) 
(median age 47 yrs, 17M/8F) with hematologic malignancies (13 
AML, 4 NHL, 3 ALL, 3 MDS, 1 CML, 1 CLL) who underwent 
PBSCT utilizing HLA matched sibling donors. Pts received 
cyclophophamide and fractionated TBI (1400 cGy). Stem ceils 
were depleted of CDS+CD3+ T ceils with antibody coated high 
density microparticles (CD8-HDM, Biotransplant, Charlestown, 
MA). 20/25 were transplanted for advanced isease. GVHD pro- 
phylaxis consisted of tacrolimus (0.02mg/kg 1VCI daily) alone 
without methotrexate. Donors were mobilized with filgastrim (10 
mcg/kg/d x 5d) prior to stem cell collection. The median number 
of CD34+ cells infused was 5.9 x 10e6/kg (range, 2.1-22.1 x 
10e6/kg), 80% recovery. The number of CD3+CD4+ cells/kg 
infused was 5.3 x 10e7/kg (range, 1.8-9.0 x 10e7/kg) while the 
number of CD3+CD8+ cells was 1.9 x 10e5/kg (range, 0.1-5.2 x 
10eS/kg), >99% depletion. All patients engrafted. An absolute 
neutrophil count of 500/1 was achieved on Day +10 (range, 9-12). 
Sustained platelet counts of 20, 00W1 were attained on Day +14 
(range, 8-42). Chilnerism studies revealed 98-100% donor cells in 
17/17 pts tested. At 3 mouths, CD4+ T cells in peripheral blood 
outnumber CD8 + T cells. The CD4/CD8 ratio was 2.5 (range 
0.8-11.9). Most of the CD4+ cells were CD45RO+ while the 
majority of CD8 cells were CD45RA+. Grades 2-4 acute GVIID 
occurred in 11/25 patients (44%). Two patients have limited 
chronic GVItD. With a median follow-up of 270 days (range, 
123-376), 20/25 patients (80%) are alive, NED. There have been 
4 transplant related deaths (1 pneumonitis, 1 hepatic veno-occlu- 
sive disease, I Listeria meningitis, 1 GVHD) and 1 relapse. Our 
results suggest hat depletion of CDS+ T cells from mobilized 
blood with the CD8-HDM device does not hinder hematopoietic 
recove W after allo-PBSCT. The incidence of acute GVttD was 
less than that reported in pts receiving a calcineurin inhibitor 
aIone as the sole form of GVHD prophylaxis. Further follow-up is 
needed to determine the effects of CD8 depletion on rates of 
chronic GVHD and relapse. 
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INFLIXIMAB FOR GVHD THERAPY IN CHILDREN 
Sleight, Bd; Cl:mT, K.:; Serrmm, A); Gil'ma,, A.; 1. Pediatries, Yale 
U, iversity, New Haven, CT; 2. 3lID Ancterso17 Ca,cer Ce~tte'r, Holts- 
ton, TX; 3. C/:ildreTz's Mercy Hospital, K:msas City, MO. 
Infliximab inhibits TNF% a major mediator of GVHD patho- 
genesis. In this retrospective r view, we analyzed the use, response 
and to,city of infliximab given for 33 episodes of GVHD in 24 
children. Ages ranged from 4 too-18 yrs (median 5y), with 18 sub- 
jects <10 yo. Diagnoses included ALL (I 1), AML (4), SAA (4), and 
1 each with ALD, NHL, Fanconi's anemia, Hurler and Omenn's 
syndrome. Eighteen patients had 25 episodes of aGVHD. Sixteen 
had steroid refractory aGVHD, in addition, 6/18 subjects were 
refractory to ATG (3) +/or daclizumab (4). At initiation of inflix- 
imab, episodes of aGVHD were grade I-Ii (1I) and grade III-IV 
(14). Infli~mab (10 mg/kg) was administered I-3x per week. Dos- 
ing frequency was increased for 2 patients with protein-losing 
enteropathy. In aGVHD patients, 110 total doses were given 
(range 1-58; median 3 doses per flare). Many patients with signifi- 
cant GVt ID or symptoms received infliximab combined with 
other immunosuppressants i cluding: initiation of or an increased 
dose of MP (3), daclizumab (4), ATG (3), plaquenil (2), MMF (2), 
thalidomide (1), fludarabine (1) an d photopheresis (1). Of evalu- 
able patients, improvement was se~n in 15/16 (94%) episodes of 
skin GVHD [CR I3/16 (81%)] and 11/14 (79%) episodes of G1 
GVHD [CR 11/14 (79%)]. One of 3 cases of liver GVHD 
responded. Responses were assessed as the best response within 56 
days after starting infliximab. Only 2 of 18 subjects with aGVHD 
are  surviving. Eight patients had 9 episodes of extensive cGVHD. 
Several patients were treated for an acute flare of cGVHD. The 
majority of patients were receiving steroids, TAC/CsA and 
plaquenil. One patient had recently received 2CDA and 2 started 
daclizumab shortly before infliximab. 426 doses of infliximab 
(10mg/kg) were given (range 5-I62; median 16 doses). Two 
patients received 157 and 162 doses, resp. Five of 8 patients 
improved. Only 3 of 8 subjects with cGVHD are surviving with 
many deaths attributed to cGVHD. Prolonged high-dose inflix- 
imab therapy was well tolerated. No infusion related adverse 
events occurred. Many infectious complications (bacterial, viral, 
fimgal) developed as a result of lnuhi-modality imnmnosuppres- 
sion in these high-risk patients. No cases of mycobacterial infec- 
tions were seen. No increased rate nor predominant type of infec 
tion was noted. Infliximab has activity in children with acute and 
chronic GVHD and warrants prospective analysis. 
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MODULATION OF HOST DENDRITIC CELLS BY EXTRACORPOREAL 
PHOTOPHORESIS IN AN ALLOGENEIC BONE MARROW TRANSPLANT 
CONDITIONING REGIMEN 
C'l:a~, G.; Miller, K.; Foss, F. Tl~'ts-New E,g:land 3,h, dical Ce,te/', 
Bosto,, k/b1. 
We demonstrated that Extracorporeal Photophorcsis (ECP) 
ameliorates chronic graft-versus-host disease (cGVHD) by 
decreasing circulating dendritic cell (DC) number and func- 
tion. To explore whether ECP could prevent GVHD through 
similar mechanisms, we transplanted 56 high-risk patients 
with a reduced intensity conditioning regimen of ECP for 2 
days, pentostatin (8rag/m2 by continuous infusion over 48 hr), 
and 600 cGy of TBI. Seven patients (2F, 5M), median age 59 
(range 32 to 70), with MI)S (n=4), AML (n=l), myelofibrosis 
(n=I), or NHL (n=l), were studied to determine the effects of 
ECP on host DC subsets prior to stem cell infusion and DC 
reconstitution. Flow cytometry used CD1 lc to identify mono 
cytoid DC1 cells and CD123 to identify plasmacytoid DC2 
cells. After the two days of ECP, DCls decreased a median of 
3% (range -39 to +35%), while DC2s decreased a median of 
47% (range -I00 to +51%). Five patients developed full donor 
mononuclear ceil and DC chimerism by day 100 with no 
grade 2-4 acute GVHD.  in this group, DC ls  and DC2s 
decreased in 2 and 4 patients respectively. Of the 2 patients 
who failed to engraft, both had decreases in DC1 and one had 
a decrease in DC2 cells. While our sample size is small, the 
data suggest hat ECP induces similar changes in DC subsets 
in these patients as in our patients with cGVHD. Since the 
overall incidence of grade 2-4 aGVHD in 56 patients was 
10%, these preliminary data suggest hat immunomodulation 
of host DCs by ECP prior to allogeneic stem cell infusion 
may play a role in reducing alloreactivity and thereby attenu- 
ate the incidence and severity of aGVHD. Further studies will 
be needed to determine whether these immunomodulatory 
effects of ECP prior to allogeneic stem cell infusion are corre- 
lated with incidence and severity of GVHD in other condi- 
tioning regimens. 
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DONOR CD8 T-CELL SUPPORT OF HEMATOPOIETIC PROGENITOR 
ACTIVITY DURING SYNGENEIC BMT 
Ha~zash, A.M.; Levy, R.B. Micribiology & Immu,ology, University of 
Miami School of MedMne, Miami, FL. 
Efforts to reduce graft vs. host disease (GVHD) during bone 
marrow transplantation (BMT) by removing donor T-cells from 
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the graft have resulted in poor engraftment and elevated isease 
recurrence. Separation of the T-cell effects supporting engraft- 
ment of hematopoietic stem/progenitor cells (HSPC) from their 
effects leading to GVHD could increase the use of this treatment 
while broadening the pool of acceptable donors. To determine if
CD8 T-cell facilitation of engraftment is limited to abrogation of 
the host's resistance, we utilized a routine syngeneic model acking 
host resistance to donor HSPC. 2x106 GFP + C57BL/6 (B6) T-cell 
depleted bone marrow cells (BM-TCD) were transplanted alone 
or in the presence of 2x106 highly enriched B6 CD8 T-cells into 
10.0 Gy lethally irradiated B6 mice. Recipient BM was harvested 
seven days later and incubated separately in IL-3 supplemented 
semi-solid culture medium. Recipients of BM-TCD and CD8 T- 
cells showed significantly greater donor colonies by fluorescent 
microscopy than recipients of only BM-TCD. It appears that 
CD4 T-cells may not share this early facilitating capacity, as illus- 
trated by an initial experiment in which day 7 post-BMT donor 
colonies were clearly not augmented by supplementing BM-TCD 
with highly enriched CD4 T-cells. Notably, the increased progen- 
itor activity in the presence of CD8 T-cells was not observed in 
recipients receiving 5.5 Gy sublethal conditioning. The require- 
ment for stronger irradiation is not apparently due to differential 
T-cell activation; GFP + B6 donor CD8 T-cells, harvested three 
days post-BMT from either 5.5 or 10.0 Gy irradiated B6 recipient 
spleen and BM, did not differentially express CD69 (not detect- 
ed), CD25 (not detected), or Sca-1 (expressed) by flow cytometric 
analysis. The ability of donor CD8 T-cells to support increased 
progenitor activity in a syngeneic BMT model suggests that their 
role in engraftment is not limited to abrogation of the host's 
resistance. Further elucidation of this early facilitating capacity 
could lead to new BMT regimens upporting engraftment with a 
decreased risk of GVHD, as well as a greater understanding of T- 
ceil biology. 
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PREVENTION OF PLATELET TA-GVHD BY USE OF INTERCEPT 
BLOOD SYSTEM 
Lin, L.; Cow,ash, L. Ceras Corporation, Comord, CA. 
Contaminating T-cells in platelet concentrates (PC) may ini- 
tiate TA-GVHD.  This study evaluated the efficacy of the 
INTERCEPT Blood System for platelets (150 btM amotosalen 
HC1 and 3 Joules/cmeUVA) for prevention of platelet TA- 
GVHD. Using molecular (DNA binding and PCR) and cellu- 
lar (LDA and ELISA) assays we have demonstrated a >105.4- 
fold reduction of viable T-cel ls in PC and inhibit ion of 
cytokine synthesis (IL8, IL lb)  during storage of INTER-  
CEPT platelets. In addition, we have demonstrated the effect 
of treatment on the development of GVHD in two in vivo 
murine transfusion models. In one model, transfusion of 108 
splenocytes from homozygous parent (A) donors into 
immunocolnpetent heterozygous hybrid (B6AF1) recipients 
resulted in acute TA-GVHD as evidenced by splenomegaly, 
donor T-cell engraftment (35%), immune suppression (4-fold 
reduction in thymocyte count), histologic evidence of GVHD 
in liver, spleen, bone marrow, and skin with transient pancy- 
topenia, progressive weight loss, hunching, and mortality. In 
contrast, B6AF1 recipients of treated splenocytes remained 
healthy and had no evidence of GVHD as judged by the same 
parameters. In a second model, transfusion recipients were 
immunocompromised. After total body irradiation with 1100 
cGy of gamma, CBA mice were reconst ituted by T-cel l -  
depleted bone marrow (BM) transplantation from B10.BR 
donors. Presence of 0.5 x 106 to 3.0 x 106 splenic T-cells in 
the BM induced acute GVHD in the recipients as evidenced 
by ruffled fur, hunching, weight loss, thymus hypoplasia, his- 
tological lesions in liver and skin, and mortality (80% to 
90%). in contrast, gamma irradiated CBA who were trans- 
planted with BM containing treated, 3 x I06 to 30 x 106 
splenic T-cells remained free of signs of GVHD. Therefore, 
use of the INTERCEPT Blood System for platelets to inacti- 
vate high titers of pathogenic viruses and bacteria in PC has 
the potential to prevent TA-GVHD associated with human 
PC transfusion. 
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A ROLE FOR THE P75 BUT NOT THE P55 TNF~ RECEPTOR IN THE 
DEVELOPMENT OF IDIOPATHIC PNEUMONIA SYNDROME AFTER 
ALLOGENEIC STEM CELL TRANSPLANTATION 
Cooke, K.R.I; Olkiewic~, 1( I; Erieksol~, N.1; HildebT~amlr, G J; Li'a, C.:; 
Ferrm:a, ff.L. z 1. Pediatrics, Braze 3/lmT-ow Tramp~am Program, Uni- 
versity of Michigan Cancer Center, Ann Arbor, MI; 2. UJzive*'sity of 
Florida, College of 3/iedici~ze, Gaimville, FL. 
Idiopathic pneumonia syndrome (IPS) is a major complication 
of allogeneic SCT and recent studies have demonstrated a casual 
role for TNFo~ in the development of this process. The inflam- 
matory effects of TNFc~ are transduced via signaling through 
either the p55 or p75 TNF receptor (TNFR). Although the p55 
receptor is believed to be more important in mediating TNF- 
induced cytotoxicity, the p75 TNFR also contributes to this 
process both via its own signaling mechanism and by regulating 
the access of TNFc~ to the p55 TNFR. We examined the contri- 
bution of each TNFR to the development of IPS by using an 
established routine SCT model across minor histocompatibility 
differences (LP --+ B6). Wild type (wt) B6 mice or B6 animals 
deficient in either the p55 (p55 -/-) or p75 (p75 -/-) receptor 
were lethally irradiated and received BM and T cells from either 
allogeneic (LP/J) or syngeneic (B6) donors. Mice were subse- 
quently monitored for the development of IPS and systemic 
GVHD. At week 6 after SCT, examination of coded lung samples 
demonstrated that p75 -/- recipients of allogeneic SCT devel- 
oped significantly less lung histopathology compared to wt con- 
trois (1.9 _+ 0.3 vs. 6.4 _+ 0.7; p > 0.0I). These findings were asso- 
ciated with reductions in BAL fluid total cellularity (1.l _+ 0.2 x 
106 vs. 2.5 _+ 0.5 x 106; p < 0.01) and CD8+ T lymphocytes. 
However, BAL fluid TNF~ levels were comparable between both 
allogeneic groups, p75 -/- allogeneic SCT recipients also demon- 
strated reduced target organ GVHD (liver and intestine; p < 
0.05) but not systemic GVHD (mortality, clinical score) com- 
pared to wt controls. Although p55 -/- animals had a significant 
survival advantage compared to wt controls, the absence of the 
p55 receptor had no effect on the severity of IPS or target organ 
GVHD. These data demonstrate a role for the p75 TNFR in the 
development of IPS in this SCT model and support the hypothe- 
sis that disruption of TNFR:TNFc~ receptor:ligand interactions 
may represent a novel strategy to prevent or treat acute lung 
inju W in the clinical setting. Furthermore, these findings reveal 
differential effects of the p55 and p75 TNFRs in GVHD induc- 
tion; absence of the p55 TNFR in allogeneic SCT recipients is 
associated with improved survival, however the p75 receptor 
appears to be critical to target organ damage that develops in sur 
viving animals. 
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SINGLE-AGENT TACROLIMUS FOR PROPHYLAXIS OF ACUTE GRAFT- 
VERSUS-HOST DISEASE AFTER RELATED ALLOGENEIC PERIPHERAL 
BLOOD STEM CELL TRANSPLANTATION: A PHASE II STUDY 
Schwartz, J.E/; BuchBarker, D.M/; Grif]k~, D.L/; de k/Iagalhaes- 
Silvelwlml, 111.2; Donnenberg, A.D/; Rybka, kV.B.S; Ball, E.D.4; Yea- 
ge'~, A.M. 1 1. University of Pittsburgh, Pittsbut'gh, PA; 2. University of 
Iowa, Iowa City, L4; 3. Milton S. Hershey Medieal Cemer, Hershey, 
PA; 4. University of GdiJb~vzia San Diego, San Diego, CA. 
Single-agent tacrolimus (TAC; FK-506) is effective prophylmvis 
for acute graft-versus-host disease (GVHD) after allogeneic bone 
marrow transplantation (BMT) from HLA-matched related 
donors (Fay JW et al., Blood 1996; 87(8): 3514-9) but has not 
been previously evaluated as single-agent GVHD prophylaxis 
after allogeneic peripheral blood stem celI transplantation 
(PBSCT). We evaluated single-agent TAC in 31 patients (median 
age, 43 years; range: 19-60)with ematologic malignancies (30) or 
common variable immunodeficiency (1) who received PBSCTs 
from related 5/6 (2) or 6/6 (29) HLA matched onors. All patients 
received a preparative regimen of oral busulfan (16mg/kg) and 
cyclophosphamide (120mg/kg). Tacrolimus was initiated at 0.03 
mg/kg/d intravenously, and the dosage was adjusted to maintain 
TAC levels between 5-15 ng/ml. Patients were continued on oral 
maintenance TAC until 6 months after PBSCT. Nine patients 
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